This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Monitoring
Summary of Prescibing Information
Median rwPFS (primary endpoint) was significantly longer among patients who received PALBACE® in combination with letrozole versus letrozole alone.1,*
Adapted from DeMichele A, et al. 2021.1
*rwPFS was defined as the number of months from start of PALBACE® in combination with letrozole or letrozole alone to death or disease progression. Disease progression was determined by the record assessment of the treating clinician based on radiology, pathology, clinical assessment or laboratory evidence. Patients who did not die or have disease progression were censored at the date of initiation of next line of therapy for those with 2 or more lines of therapy or their last visit during the study period (February 2015-May 2019) for patients with only 1 line of therapy.
After sIPTW adjustment, median follow-up was 24.2 and 23.3 months for PALBACE® in combination with letrozole and letrozole alone, respectively.1
CI, confidence interval; HR, hormone receptor; LET, letrozole; n, total number of patients; PFS, progression-free survival; rwPFS, real-world
progression-free survival; sIPTW, stabilised inverse probability treatment weighting.
References:
Please click the Prescribing Information link to view the safety and adverse events information of PALBACE®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
All images used are for representation purposes only
(®)Trademark Proprietor: Pfizer Inc.USA Licensed User: Pfizer Products India Private Limited.India
PP-IBR-IND-0626 September 2023
Events, materials and videos
PALOMA was the first clinical trial programme to explore how a CDK4/6 inhibitor could benefit women with HR+/HER2- mBC
Recommended dosing schedule and dose modifications for AEs
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.